A multicenter prospective study of Taohong Siwu Decoction in the prevention and treatment of vascular calcification in patients with chronic kidney disease
- Conditions
- Chronic renal failure
- Registration Number
- ITMCTR2000004025
- Lead Sponsor
- Shuguang Hospital, affiliated to Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1)The signing of the informed consent.
(2)Aged 18-80 years.
(3)The patients with ckd5 of chronic renal failure were blood stasis syndrome.
(4)There were early abnormal bone metabolism or calcium and phosphorus metabolism.
(1)People with serious primary diseases such as heart, brain, liver and hematopoiesis.
(2)After kidney transplantation, patients with psychosis or diabetic.
(3)Patients with acute renal failure.
(4)Pregnant or lactating women.
(5)Patients who are known to be allergic to the drugs used.
(6)People who are participating in other drug clinical trials or in other clinical trials within 3 months or other drugs that have been used to control thrombus.
(7)Other circumstances in which the researcher considers it inappropriate to participate in this study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fibroblast Growth Factor23;Fetuin A;Vitamin D3;Pulse wave velocity;Arterial enhancement index;alkaline phosphatase;Blood phosphorus;Asymmetric-dimethylation arginine;blood calcium;Matrix Gla protein;Calcitonin;parathyroid hormone;Brachial ankle index;bone morphogenetic protein-2;Bone density;Klotho;
- Secondary Outcome Measures
Name Time Method Superoxide dismutase;C-reactive protein;Malondialdehyde;Interleukin-;